降糖治疗与2型糖尿病心力衰竭:机制联系、临床数据与未来方向
2型糖尿病独立增加心衰风险与死亡,血糖达标不能消除该风险。该综述系统回顾现有及新型降糖药的生物学靶点、作用机制及其与心衰的关系,并基于心血管结局试验数据指出证据缺口与未来研究方向。
要点
- 降糖药对心衰风险影响不一,需关注心血管结局试验中的心衰事件。
- 血糖控制水平不足以充分反映心血管风险。
- 心衰事件已越来越多作为心血管结局试验的复合或次要终点。
核心结论
- 糖尿病独立增加心衰风险与死亡,血糖优化不能消除该风险。
- 不同降糖治疗对心衰的风险与获益存在差异。
研究设计与样本
- 综述系统回顾现有及新型降糖药的靶点、机制及与心衰的关系。
- 基于FDA监管要求下开展的大型心血管结局试验证据。
主要发现
- 新型与现有降糖治疗在心血管结局试验中显示对心衰的风险与获益不一。
- 心血管结局试验越来越将心衰事件纳入主要复合终点或次要裁定终点。
临床怎么用
- 评估降糖治疗时应关注心血管结局试验中的心衰事件数据。
- 不应仅以血糖控制指标判断心血管风险。
局限性
- 现有证据在降糖治疗与心衰关系方面存在缺口。
- 需要未来研究完善新兴降糖治疗评估中心衰相关数据的确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diabetes mellitus independently increases the risk of and mortality from heart failure in a manner that is well established but inadequately understood. Glycemic optimization does not eliminate this risk, and measures of glycemic control are insufficient markers of cardiovascular risk. In response to a regulatory guidance from the US Food and Drug Administration, glucose-lowering agents are now routinely evaluated in large cardiovascular outcome trials. These recent trial experiences of novel and established glucose-lowering therapies have shown variable risks and benefits with respect to heart failure. Cardiovascular outcome trials have increasingly included heart failure events as either a component of the primary end point or a secondary adjudicated end point. We comprehensively review each established and novel currently marketed glucose-lowering therapy, their biological targets, mechanisms of action, and relationships with heart failure. We then highlight gaps in available evidence and directions for future research regarding the ascertainment of heart failure-related data in the evaluation of emerging glucose-lowering therapies.
引用
- Vijayakumar S, Vaduganathan M, Butler J, et al. Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions. Circulation. 2018. PMID: 29506996. doi:10.1161/CIRCULATIONAHA.117.032099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。